Surfaxin is a drug owned by Lees Pharmaceutical Hk Ltd. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 17, 2013. Details of Surfaxin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5407914 | Pulmonary surfactant protein and related polypeptides |
Nov, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Surfaxin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Surfaxin's family patents as well as insights into ongoing legal events on those patents.
Surfaxin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Surfaxin's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 17, 2013 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Surfaxin Generics:
There are no approved generic versions for Surfaxin as of now.
About Surfaxin
Surfaxin is a drug owned by Lees Pharmaceutical Hk Ltd. It is used for preventing respiratory distress syndrome in premature infants. Surfaxin uses Lucinactant as an active ingredient. Surfaxin was launched by Lees Pharm Hk in 2012.
Approval Date:
Surfaxin was approved by FDA for market use on 06 March, 2012.
Active Ingredient:
Surfaxin uses Lucinactant as the active ingredient. Check out other Drugs and Companies using Lucinactant ingredient
Treatment:
Surfaxin is used for preventing respiratory distress syndrome in premature infants.
Dosage:
Surfaxin is available in suspension form for intratracheal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 8.5ML | SUSPENSION | Discontinued | INTRATRACHEAL |